| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the
1 From the Department of Internal Medicine, The University of Texas Southwestern Medical School at Dallas, Dallas, Texas 75235
The identity of the nonpolar transformation products of testosterone-1,2-3H, the time course of the appearance of these metabolites in various tissue compartments, and the subcellular distribution of testosterone and its metabolites in prostate have been investigated following the intravenous administration of the hormone to normal and to functionally hepatectomized rats. Evidence has been obtained in both types of animals that within 1 min following its administration testosterone is taken up by the prostate, and at least 90% is converted to three products, androstandiol, dihydrotestosterone, and androsterone. From prostatic nuclei, however, only testosterone-3H and dihydrotestosterone-3H were recovered for as long as 2 hours following testosterone injection. Furthermore, it has been shown that in the presence of a NADPH2-generating system prostatic nuclei convert testosterone to dihydrotestosterone, whereas prostatic cytoplasm, in addition, reduces dihydrotestosterone to androstandiol. The nuclear enzyme which performs this reaction has been partially characterized and appears to be located within the chromatin. Finally, the tissue distribution of dihydrotestosterone-3H has been investigated at a short time interval following testosterone-1,2-3H injection; this metabolite was detected only in prostate, seminal vesicle, preputial gland, kidney, and plasma.
The Conversion of Testosterone to 5
-Androstan-17ß-ol-3-one by Rat Prostate in Vivo and in Vitro
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Vasaitis, A. Belosay, A. Schayowitz, A. Khandelwal, P. Chopra, L. K. Gediya, Z. Guo, H.-B. Fang, V. C.O. Njar, and A. M.H. Brodie Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3{beta}-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer Mol. Cancer Ther., August 1, 2008; 7(8): 2348 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Wierman, R. Basson, S. R. Davis, S. Khosla, K. K. Miller, W. Rosner, and N. Santoro Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3697 - 3710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Bianco, S. J. McPherson, H. Wang, G. S. Prins, and G. P. Risbridger Transient Neonatal Estrogen Exposure to Estrogen-Deficient Mice (Aromatase Knockout) Reduces Prostate Weight and Induces Inflammation in Late Life Am. J. Pathol., June 1, 2006; 168(6): 1869 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lin, J. Kokontis, F. Tang, B. Godfrey, S. Liao, A. Lin, Y. Chen, and J. Xiang Androgen and its receptor promote bax-mediated apoptosis. Mol. Cell. Biol., March 1, 2006; 26(5): 1908 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Rosner Proscar and Propecia--A Therapeutic Perspective J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3096 - 3098. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Mohler, C. W. Gregory, O. H. Ford III, D. Kim, C. M. Weaver, P. Petrusz, E. M. Wilson, and F. S. French The Androgen Axis in Recurrent Prostate Cancer Clin. Cancer Res., January 15, 2004; 10(2): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Anderson, A. M. Wallace, N. Sattar, N. Kumar, and K. Sundaram Evidence for Tissue Selectivity of the Synthetic Androgen 7{alpha}-Methyl-19-Nortestosterone in Hypogonadal Men J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2784 - 2793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Bianco, D. J. Handelsman, J. S. Pedersen, and G. P. Risbridger Direct Response of the Murine Prostate Gland and Seminal Vesicles to Estradiol Endocrinology, December 1, 2002; 143(12): 4922 - 4933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Rebbeck Inherited Genotype and Prostate Cancer Outcomes Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Nahoum, A. Gangloff, P. Legrand, D.-W. Zhu, L. Cantin, B. S. Zhorov, V. Luu-The, F. Labrie, R. Breton, and S.-X. Lin Structure of the Human 3alpha -Hydroxysteroid Dehydrogenase Type 3 in Complex with Testosterone and NADP at 1.25-A Resolution J. Biol. Chem., November 2, 2001; 276(45): 42091 - 42098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Mahendroo, K. M. Cala, D. L. Hess, and D. W. Russell Unexpected Virilization in Male Mice Lacking Steroid 5{alpha}-Reductase Enzymes Endocrinology, November 1, 2001; 142(11): 4652 - 4662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Long, D. N. Grigoryev, I. P. Nnane, Y. Liu, Y.-Z. Ling, and A. M. Brodie Antiandrogenic Effects of Novel Androgen Synthesis Inhibitors on Hormone-dependent Prostate Cancer Cancer Res., December 1, 2000; 60(23): 6630 - 6640. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Jaffe, S. B. Malkowicz, A. H. Walker, S. MacBride, R. Peschel, J. Tomaszewski, K. Van Arsdalen, A. J. Wein, and T. R. Rebbeck Association of SRD5A2 Genotype and Pathological Characteristics of Prostate Tumors Cancer Res., March 1, 2000; 60(6): 1626 - 1630. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Anderson, C. W. Martin, A. W. C. Kung, D. Everington, T. C. Pun, K. C. B. Tan, J. Bancroft, K. Sundaram, A. J. Moo-Young, and D. T. Baird 7{alpha}-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3556 - 3562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Wright, R. C. Douglas, L. N. Thomas, C. B. Lazier, and R. S. Rittmaster Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5{alpha}-Reductase Endocrinology, October 1, 1999; 140(10): 4509 - 4515. [Abstract] [Full Text]
|
|
|
|
|
|
I. P. Nnane, K. Kato, Y. Liu, B. J. Long, Q. Lu, X. Wang, Y.-z. Ling, and A. Brodie Inhibition of Androgen Synthesis in Human Testicular and Prostatic Microsomes and in Male Rats by Novel Steroidal Compounds Endocrinology, June 1, 1999; 140(6): 2891 - 2897. [Abstract] [Full Text]
|
|
|
|
|
|
B. A. Foster and G. R. Cunha Efficacy of Various Natural and Synthetic Androgens to Induce Ductal Branching Morphogenesis in the Developing Anterior Rat Prostate Endocrinology, January 1, 1999; 140(1): 318 - 328. [Abstract] [Full Text]
|
|
|
|
|
|
D. E. Cummings, N. Kumar, C. W. Bardin, K. Sundaram, and W. J. Bremner Prostate-Sparing Effects in Primates of the Potent Androgen 7{alpha}-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4212 - 4219. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Katashima, K. Yamamoto, Y. Tokuma, T. Hata, Y. Sawada, and T. Iga Pharmacokinetic and Pharmacodynamic Study of a New Nonsteroidal 5alpha -Reductase Inhibitor, 4-[3-[3-[Bis(4-Isobutylphenyl)Methylamino]Benzoyl]-1H-Indol-1-yl]-Butyric Acid, in Rats J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 914 - 920. [Abstract] [Full Text]
|
|
|
|
 |
|
 H.-K. Lin, J. M. Jez, B. P. Schlegel, D. M. Peehl, J. A. Pachter, and T. M. Penning Expression and Characterization of Recombinant Type 2 3{alpha}-Hydroxysteroid Dehydrogenase (HSD) from Human Prostate: Demonstration of Bifunctional 3{alpha}/17{beta}-HSD Activity and Cellular Distribution Mol. Endocrinol., December 1, 1997; 11(13): 1971 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Katashima, K. Yamamoto, K. Haraguchi, Y. Tokuma, T. Hata, Y. Sawada, and T. Iga Tissue Distribution Kinetics of a New Nonsteroidal 5alpha -Reductase Inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol1-yl]-butyric Acid, in Rats Drug Metab. Dispos., September 1, 1997; 25(9): 1051 - 1058. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. B. Pratt and D. O. Toft Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones Endocr. Rev., June 1, 1997; 18(3): 306 - 360. [Abstract] [Full Text]
|
|
|
|
 |
|
 T.-M. Lin and C. Chang Cloning and characterization of TDD5, an androgen target gene that is differentially repressed by testosterone and dihydrotestosterone PNAS, May 13, 1997; 94(10): 4988 - 4993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Benghuzzi, B. G. England, and P. K. Bajpai The Effects of Long-Term Sustained Delivery of Dihydrotestosterone by Poly(lactic acid) Impregnated and Noncoated Biodegradable Ceramic Devices in Male Rodents Journal of Bioactive and Compatible Polymers, January 1, 1991; 6(2): 115 - 128. [Abstract] [PDF]
|
|
|
|
 |
|
 C. W. Bardin, L. Bullock, G. Schneider, J. E. Allison, and A. J. Stanley Pseudohermaphrodite Rat: End Organ Insensitivity to Testosterone Science, February 20, 1970; 167(3921): 1136 - 1137. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Stern and A. J. Eisenfeld Androgen Accumulation and Binding to Macromolecules in Seminal Vesicles: Inhibition by Cyproterone Science, October 10, 1969; 166(3902): 233 - 235. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
